Navigation Links
Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
Date:9/7/2007

SAN FRANCISCO, Sept. 7 /PRNewswire/ -- Roche announced today that three clinical data abstracts about its oral chemotherapy treatment Xeloda have been accepted for presentation at the 2007 Breast Cancer Symposium in San Francisco, Sept. 7 and 8.

Two of the abstracts include data from the XeNA (Xeloda in NeoAdjuvant) trial, a study of Xeloda and docetaxel with or without Herceptin in patients with invasive breast cancer. The third presentation highlights findings that validate efficacy and cost benefits of Xeloda in breast cancer patients.

-- Poster No. A54, [General Poster Session A, Sept. 7, 12:00 - 12:45

p.m.], "Frequency of circulating tumor cells (CTCs) in an open-label

study of neoadjuvant capecitabine, docetaxel and trastuzumab (CDT)

combination therapy in patients with HER2+ breast cancer (BC)."

(Presenter: Stefan Gluck)

-- Poster No. 100, [General Poster Session C, Sept. 8, 7:00 - 8:00 a.m.],

"Distribution of p53 mutations by AmpliChip assay in patients receiving

neoadjuvant capecitabine (C) plus docetaxel (D) with or without

trastuzumab (T) for newly diagnosed breast cancer (BC)." (Presenter:

Nancy Patten)

-- Poster No. A41, [General Poster Session D, Sept. 8, 11:45 a.m. - 12:45

p.m.], "Capecitabine is associated with fewer adverse events than other

standard therapies in patients with breast cancer: a claims database

analysis." (Presenter: Hope Rugo, M.D.)

These studies affirm Roche's commitment to exploring the expanded use of Xeloda in combination with new therapies. Additionally, the data explore the potential of oral Xeloda to offer effective treatment with a lower incidence of adverse events compared with traditional intravenous chemotherapy.

About Xeloda

Xeloda is the only FDA-approved oral chemotherapy for both metastatic breast cancer and adjuvant and metastatic colorectal cancer. Inactive in pill for
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... -- - Cross reference: Picture is available ... Hitachi Medical Systems Europe è lieta ... all,ECR 2015. Si tratta di un sistema di ... che migliora la capacità diagnostica dei sistemi già esistenti ... paziente. Le nuove funzionalità di OASIS permettono una migliore ...
(Date:3/5/2015)... , Mar. 05, 2015 Research and Markets ... of the "Japan Pharma Outlook 2015: Year to ... Strategic Initiatives" report to their offering. ... Japan from April -2014 (Annexure 1) is ... companies - whether generic or innovator. The most of ...
(Date:3/5/2015)... 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ... commercialization of targeted antiviral therapies, announced today that it ... Conference, to be held March 8-11, 2015, in ... James Sapirstein , Chief Executive Officer, will provide an ... and will be available to participate in one-on-one meetings ...
Breaking Medicine Technology:Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 2Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 3Hitachi Medical Systems Europe lancia la nuova generazione di OASIS*: Il sistema di RM aperta ad alto campo da 1.2 T. Ancora più valore al paziente 4Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 2Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 3ContraVir to Present at 27th Annual ROTH Conference 2
... AM MAIN, Germany, October 21, 2011 ... International Dystonia Symposium (IDS)   in Barcelona, Spain (20-22 ... data concerning the long-term, sustained efficacy and safety of ... treatment of patients with dystonia. Dystonia ...
... Components is a leading manufacturer of disposable gas cartridges ... world. Specializing in medical gas cylinders , iSi Components ... cylinders are an incredibly diverse product that have many applications ... different sizes and gas fills. iSi Components provides gas cylinders ...
Cached Medicine Technology:Merz research Shows Long-term Benefits for Patients With Dystonia 2Merz research Shows Long-term Benefits for Patients With Dystonia 3Merz research Shows Long-term Benefits for Patients With Dystonia 4Disposable Gas Cylinders from iSi Components: Custom Engineered to Your Specifications 2
(Date:3/5/2015)... Supply & Demand Chain Executive Magazine has ... Know” in the supply chain industry, and we are ... team were included on this year’s list! Russ King ... due to their hard work, their commitment to excellence, ... resolving client needs and challenges. , Russ ...
(Date:3/5/2015)... 05, 2015 Dr. Jonathan Glashow a ... ) has been named by Castle Connolly ... area. Dr. Glashow has been selected by Castle Connolly ... the top specialty care doctors in the tri-state metropolitan ... Connolly program, which carefully screens and selects doctors through ...
(Date:3/5/2015)... As a result of the American ... Clearstream, LLC ’s products, services and company philosophies, ... products—led by their mPulse Hand Sanitizer—fits the core ... The AAPA—which represents a profession comprising than 100,000 ... specialties in the U.S.—advocates and educates on behalf ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Today, ... now running on 100% pollution-free electricity through a ... , As an Arcadia Power Clean Energy ... (EPA) Green Power Partnership requirements, joining national brands ... also purchase clean energy. Earth Source Organics joins ...
(Date:3/5/2015)... Park, California (PRWEB) March 05, 2015 ... (JCAP) last week released a special issue ... in the field of PANDAS (Pediatric Autoimmune Neuropsychiatric ... Neuropsychiatric Syndromes), an autoimmune reaction triggered by infections ... lyme, which result in inflammation of the child's ...
Breaking Medicine News(10 mins):Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 3
... has been found that elders in hospitals and care homes are ... this, many of them are said to be in hunger// for ... Ivan Lewis. ,Commencing the ‘Dignity for older people’ campaign ... people should be thoroughly understood. When the food is kept far ...
... Pennsylvania School of Medicine have described a new type ... the patient's thoughts, providing two-way signaling for motor control ... at a junction now of developing a new approach ... Smith, MD, Professor of Neurosurgery and Director of the ...
... Scientists have unlocked the secrets of a deadly superbug that attacks ... ,The news is a vital first step in attempts to ... resistant to current antibiotic treatments. ,Already responsible for ... stages of an epidemic that could result in a massive death ...
... study, published in the March 1, 2007 issue of CANCER, ... termination of this highly effective breast cancer drug may negatively ... that over one third of women have ceased tamoxifen treatment. ... quarter of women treated for breast cancer stop tamoxifen within ...
... traits shape up in natural populations,// but one is led ... Two theories have tried to address this challenge – the ... ,The theory of hitchhiking has indicated that genes ... in natural populations when they "hitch a ride" with healthier ...
... whatever the color”, says Dr.Clive Anderson, consultant dermatologist and ... address is part of a move to get Jamaicans ... of the island’s youth resort to bleaching or lightening ... ,Government health officials plan to launch a ...
Cached Medicine News:Health News:New Ideas on Developing Thought-Controlled Artificial Limbs 2Health News:Tamoxifen Discontinuation Rates Surprisingly High 2Health News:The Evolution of Costly Traits 2
... Ziemer's FEMTO LDV, the first compact, mobile ... provide a versatile, powerful platform for a ... The basic system addresses the demand of ... that is consistent with an efficient LASIK ...
Stylish yet conservative, these classics are reliable, comfortable and durable....
Safilo Design, a state-of-the art ophthalmic collection that blends technology with minimalist sophistication. Each style comes with a sleek silver-colored hard case with magnetic closure....
Inquire...
Medicine Products: